Investment Thesis
CytoDyn exhibits severe financial distress with negative stockholders' equity of -$119.7M, indicating the company is technically insolvent. The company has zero revenue, massive operating losses of -$26.6M, and is burning cash at -$6.8M annually with only $5.0M in cash reserves. The balance sheet shows liabilities exceeding assets by $119.7M, creating an unsustainable capital structure.
Strengths
- Slight improvement in net loss year-over-year (loss narrowed by 65.6%, though still deeply negative)
- Minimal capital expenditure ($30K) suggests company has eliminated discretionary spending
- Still maintains $5.0M in cash reserves providing limited runway
Risks
- Negative stockholders' equity of -$119.7M indicates technical insolvency and high bankruptcy risk
- Zero revenue generation with no apparent path to commercialization
- Massive cash burn of -$6.8M annually against only $5.0M in cash reserves (less than 1 year of runway)
- Current ratio of 0.10x indicates severe liquidity crisis and inability to meet short-term obligations
- Operating losses of -$26.6M with no revenue offsetting expenses
- Long-term debt of $42.2M on nearly-worthless asset base with negative equity
Key Metrics to Watch
- Cash burn rate and remaining months of cash runway
- Whether company achieves any revenue or FDA approval for pipeline assets
- Debt restructuring or refinancing announcements
- Additional equity dilution from capital raises needed for survival
Financial Metrics
Revenue
0.0
Net Income
-28.1M
EPS (Diluted)
$-0.02
Free Cash Flow
-6.8M
Total Assets
8.9M
Cash
5.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-315.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.10x
Quick Ratio
0.10x
Debt/Equity
N/A
Debt/Assets
1,440.2%
Interest Coverage
-2.33x
Long-term Debt
42.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T08:12:12.435352 |
Data as of: 2025-11-30 |
Powered by Claude AI